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Glucagon counterregulation (GCR) protects against hypoglycemia, but is impaired in type
1 diabetes (T1DM). A model-based analysis of in vivo animal data predicts that the GCR
defects are linked to basal hyperglucagonemia.To test this hypothesis we studied the rela-
tionship between basal glucagon (BasG) and the GCR response to hypoglycemia in 29
hyperinsulinemic clamps in T1DM patients. Glucose levels were stabilized in euglycemia
and then steadily lowered to 50mg/dL. Glucagon was measured before induction of hypo-
glycemia and at 10min intervals after glucose reached levels below 70mg/dL. GCR was
assessed by CumG, the cumulative glucagon levels above basal; MaxG, the maximum
glucagon response; and RIG, the relative increase in glucagon over basal. Analysis of
the results was performed with our mathematical model of GCR. The model describes
interactions between islet peptides and glucose, reproduces the normal GCR axis and its
impairment in diabetes. It was used to identify a control mechanism consistent with the
observed link between BasG and GCR. Analysis of the clinical data showed that higher
BasG was associated with lower GCR response. In particular, CumG and RIG correlated
negatively with BasG (r =−0.46, p = 0.012 and r =−0.74, p < 0.0001 respectively) and
MaxG increased linearly with BasG at a rate less than unity (p < 0.001). Consistent with
these results was a model of GCR in which the secretion of glucagon has two compo-
nents.The ﬁrst is under (auto) feedback control and drives a pulsatile GCR and the second
is feedback independent (basal secretion) and its increase suppresses the GCR. Our sim-
ulations showed that this model explains the observed relationships between BasG and
GCR during a three-fold simulated increase in BasG. Our ﬁndings support the hypothesis
that basal hyperglucagonemia contributes to the GCR impairment inT1DM and show that
the predictive power of our GCR animal model applies to human pathophysiology inT1DM.
Keywords: glucagon, counterregulation, diabetes mellitus, hyperglucagonemia, feedback, hypoglycemia, intrapan-
creatic network, mathematical model
INTRODUCTION
Defective hormonal counterregulation is the primary obstacle to
safely achieving tight blood glucose (BG) control in type 1 diabetes
(T1DM) and may result in up to threefold excess of severe hypo-
glycemia [The Diabetes Control and Complications Trial Research
Group, 1993; UK Prospective Diabetes Study Group ,UKPDS; The
Action to Control Cardiovascular Risk in Diabetes Study Group,
2008]. In health, hypoglycemia defenses include in the order of
their activation (Cryer and Gerich, 1983; Gerich, 1988): (i) reduc-
tion in β-cell insulin secretion, (ii) glucagon release from the
pancreas, (iii) secretion of epinephrine by the adrenalmedulla, (iv)
sympathetic nervous system activation, (v) cortisol and growth
hormone secretion, and (vi) hepatic auto-regulation. In T1DM,
Abbreviations: AFI, auto-feedback independent glucagon secretion; AFR, auto-
feedback regulated glucagon secretion; BasG, basal glucagon; BG, blood glucose;
CumG, cumulated glucagon levels above basal; GCR, glucagon counterregulation;
MaxG, maximum glucagon response; RIG, relative increase in glucagon over basal;
T1DM, type 1 diabetes mellitus.
effective reduction in insulin secretion is not possible and the
glucagon counterregulation (GCR) gradually disappears during
the course of the disease (Gerich et al., 1973; Fukuda et al., 1988;
Hoffman et al., 1994) even though the glucagon secreting α-cells
in the pancreatic islets appear intact and respond to other stimuli.
The abnormal GCR presents a major barrier to the safe treat-
ment of the disease with intensive insulin therapy (Cryer, 1999,
2002; Segel et al., 2002) and even though extensively studied, the
mechanism behind the GCR impairment remains unclear. One
of the theories proposed to explain the deﬁciency in the GCR is
the “switch-off” hypothesis. It hypothesizes that α-cell activation
by hypoglycemia requires both the availability and rapid decline
of intraislet insulin and attributes the defects in GCR in T1DM
to loss of a (insulin) “switch-off” signal from the β-cells (Banarer
et al., 2002). Some support for this theory was provided by animal
(Zhou et al., 2004) and clinical data (Banarer et al., 2002).
To study the mechanisms of GCR and its impairment in T1DM
we apply a system-level approach based on the premise that the
glucagon time-dependent secretion is controlled by the action of a
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hormonal network within the endocrine pancreas. In vivo animal
and in silico studies are thus combined to reconstruct the network
mechanisms directing the glucagon release and the GCR response
to hypoglycemia and how these mechanisms change in T1DM.We
have developed a mathematical model of GCR which uniﬁes inter-
actions between islet peptides and glucose, reproduces the normal
GCR control axis, and its impairment in diabetes in rodents. Using
this model we have predicted that the GCR must be pulsatile in
nature and develop as response of an intrapancreatic hormone
feedback network to disinhibition of α-cells and hypoglycemia.We
have supported this prediction by showing that in an insulin deﬁ-
cient animal model a defective GCR can be repaired in vivo by two
different glucagon inhibiting signals (insulin and somatostatin)
which upon switch-off during hypoglycemia trigger a pulsatile
GCR response (Farhy et al., 2008). Further analysis of our rodent
experimental data led to several modiﬁcation of the initial GCR
model (see Farhy and McCall, 2009a,b, 2010, 2011), which in its
current form assumes that the secretion of glucagon has two com-
ponents. The ﬁrst component is under (auto) feedback control
and drives a pulsatile glucagon response to hypoglycemia and the
second component is feedback independent (basal secretion) and
its increase suppresses the GCR. We have shown that this model
replicatesmost of the in vivo behavior of the systemandkey experi-
mental ﬁndings including the in vivo repair of GCR in diabetic rats
by intrapancreatic infusion and termination (switch-off) during
hypoglycemia of insulin (Zhou et al., 2004; Farhy et al., 2008) and
somatostatin (Farhy et al., 2008). These additional model-based
simulations led to the prediction that GCR defects are likely linked
to basal hyperglucagonemia (Farhy and McCall, 2010, 2011). We
have also proposed clinical strategies which use α-cell inhibitors
to repair the defective GCR and stabilize insulin deﬁcient dia-
betes although no human data is yet available (Farhy and McCall,
2011). The goal of the current study is to start testing our model-
based predictions with clinical data. Accordingly, we examine here
the relationship between basal glucagon (BasG) levels and various
facets of the GCR response to insulin-induced hypoglycemia in
T1DM subjects.
MATERIALS AND METHODS
METHODOLOGY OUTLINE
Our methodology to explore the link between basal hyper-
glucagonemia and GCR impairment in T1DM involves a combi-
nation of analysis of clinical data with model-based simulations.
We use clinical data to conﬁrm that BasG levels (understood as the
glucagon concentrations during euglycemia) are negatively corre-
lated with glucagon response to hypoglycemia. Then, we use our
existingmodel of glucagon secretion to conﬁrm that it is consistent
with the clinical results in order to verify its predictive capabilities.
SUBJECTS AND PROTOCOL DESIGN
To investigate the relationship between BasG levels and GCR,
T1DMpatients were studied under controlled hospital conditions.
Participants were treated overnight with a low-dose insulin infu-
sion to attain near euglycemia and then the effects of hypoglycemia
were estimated using a clamp procedure. Twenty-nine hyperin-
sulinemic euglycemic–hypoglycemic clamps were performed on
24 patients with type 1 diabetes. The time interval between the
clamps in the ﬁve patients who were studied twice was at least
6months, which allowed us to consider them to be independent.
The study was approved by the University of Virginia Internal
Review Board and was done at the University of Virginia Gen-
eral Clinical Research Center. All study participants have signed
an informed consent form.
Study participants had a screening visit that included a history
and physical examination. Laboratory testing included a urine
microalbumin/creatinine ratio, human chorionic gonadotropin
(HCG; females), HbA1c, hematocrit, and a comprehensive chem-
istry panel. The participants were on average (mean± SD)
36.9± 12.4 years old, had had type 1 diabetes for 17.2± 9.7 years
andhadBMIof 25.7± 2.9 kg/m2.All volunteerswere treating their
diabetes (insulin pump or insulin injections) and had HbA1c of
7.9± 1.5%prior to the clamp. Before the admission,patients using
long or intermediate acting (basal) insulin consulted with a study
physician for insulin dose adjustment. Long-acting insulin was
discontinued 60 h and intermediate acting insulin was discontin-
ued 36 h prior to the clamp procedure. Only soluble (Regular)
or rapid-acting analog insulin was allowed on the day of the
admission. Participants were allowed to take their other outpa-
tient medications, but glucocorticoids were excluded. Scrupulous
avoidance of hypoglycemia was maintained in the week prior to
the study. Patients were asked to try to keep their BG between
100 and 150mg/dL and to perform frequent ﬁnger stick BG mea-
surements (10 per day, at least 30min apart) for reference values.
Participantswere admitted to theGeneral Clinical ResearchCenter
on the evening prior to study. At 21:30 h, an intravenous infusion
of soluble insulin (Novolin R,Novo Nordisk, Bagsværd,Denmark,
0.1U/mL saline) was begun and titrated to maintain the partic-
ipants’ BG overnight between 100 and 150mg/dL as measured
every 30min using a YSI analyzer (YSI Life Sciences, OH, USA).
This infusion was discontinued at 08:30 h the following morning
at the initiation of the clamp procedure.
At time 0 an insulin infusionwas given viaHarvard pump (Har-
vard Apparatus, MA, USA) as a 20mU/kg priming over 10min
followed by a constant 1mU/kg/min infusion. Plasma glucose was
measured at intervals of 5min and clamped at basal levels via
a variable-rate infusion of 20% dextrose using the equations of
DeFronzo et al. (1979). BG levels were stabilized in euglycemia
for 150min and then lowered to 50mg/dL using a previously val-
idated hypoglycemic clamping technique to ensure steady descent
into hypoglycemia (Baron et al., 1993). BG levels were maintained
at that level for 30min, and ﬁnally increased back to euglycemia.
BasG concentration (GLbasal) wasmeasured at t basal, 10min before
the start of thedescent intohypoglycemia. To assessGCR,glucagon
levels were measured every 10min from 25 to 135min after
starting the descent. Glucagon concentration was measured by
radioimmunoassay (RIA kits, Millipore, MA, USA).
MEASURES OF GCR AND STATISTICAL ANALYSIS
The following measures were used to estimate various facets of the
GCR response to hypoglycemia:
• MaxG (pg/mL): maximum GCR reached from 25 to 135min
after starting the descent into hypoglycemia.
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• CumG (pg/mL× 90min): cumulated glucagon levels above
basal (integral of the concentration of glucagon minus BasG)
computed from t 70 to t 70 + 90min where t 70 is the time when
glucose levels crossed the threshold of 70mg/dL.
• RIG(%): relative increase of glucagon computedby the formula:
RIG [% ] = MaxG − GLbasal
GLbasal
× 100%
Note that both CumG and RIG could have negative values.
An outline of the clamp procedure with an illustration of the
GCR measures used is presented in Figure 1.
The relationships between GLbasal and MaxG, CumG, and RIG
were examined using Pearson’s correlation. The analyses were per-
formedusingMATLAB7.10 (R2010a),TheMathWorks andPASW
Statistics 18, SPSS Inc. Data are presented in mean± SD.
MATHEMATICAL MODEL OF GCR
We have recently developed and validated a mathematical model
of GCR which approximates the rodent glucagon control axis and
explains most of its in vivo behavior. This model shows that α-
cell secretion is inhibited by hyperglycemia and has both basal,
or auto-feedback independent (AFI) component and pulsatile, or
auto-feedback regulated (AFR) component. In this work we use
this model to determine the extent to which it is consistent with
human data (above).
Figure 2 summarizes the interactions between BG and the α-
cells to which we refer as a minimal control network (MCN) of
glucagon secretion in the insulin deﬁcient pancreas. Background
supporting each of these interactions can be found elsewhere
(Farhy et al., 2008; Farhy and McCall, 2009a,b, 2010, 2011). We
note that the α-cell auto-feedback (Kawai and Unger, 1982) which
is the key mediator of the system dynamic properties is likely
indirect, mediated by δ-cell somatostatin [glucagon stimulates
somatostatin (Utsumi et al., 1979; Epstein et al., 1980; Kawai and
Unger, 1982; Stagner et al., 1988, 1989; Brunicardi et al., 2001)
and, in turn, somatostatin inhibits glucagon (Klaff and Taborsky,
1987; Schuit et al., 1989; Sumida et al., 1994; Kleinman et al., 1995;
Huypens et al., 2000; Portela-Gomes et al., 2000; Strowski et al.,
2000; Brunicardi et al., 2001; Cejvan et al., 2003; Ludvigsen et al.,
2004)].
To establish that the relationships shown in Figure 2 unify the
primary interactions responsible for the control of GCR, we have
approximated the MCN with a mathematical model and shown
that it explains most of the in vivo behavior of the system. The
model equation is shown below and is constructed following the
methodology outlined in (Farhy, 2004).
GL’ = −kGLGL + rGL,basal + rGL 1
1 + (BG/tBG)nBG
× 1
1 + [GL(t − DGL)/tGL]nGL (1)
Here, GL(t ) and BG(t ) are the time-dependent concentrations
of glucagon and BG, respectively; the derivative is the rate of
change with respect to time t. The half-life of glucagon determines
the elimination constant kGL. The delay DGL, the half-maximal
inhibitory doses (ID50-s), tBG, tGL, and the slopes nBG and nGL in
the auto-feedback guarantee glucagon pulsatility with a frequency
similar to that experimentally observed in rats (Farhy et al., 2008).
The slope nBG is determined so that a glucose stimulus leads to an
increase in insulin similar to that of published rat data. The secre-
tion rates rGL and rGL,basal control the amplitude of the GCR. The
physiological meaning of the parameters and the way they have
FIGURE 1 |Top: timeline of the hyperinsulinemic euglycemic–hypoglycemic clamp. Bottom: schematic presentation of the measures used to estimate the
GCR.
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been determined is explained in detail elsewhere (Farhy et al.,
2008; Farhy and McCall, 2009a,b, 2010, 2011).
The nominal values of the parameters that appear in Eq. 1
are given in Table 1 in Farhy and McCall (2010). We note that
these parameters have been determined to approximate rodent
physiology. Here, to better approximate the human glucagon lev-
els we have rescaled the values of GL by multiplying tGL, rGL,
and rGL,basal by the scaling factor 0.24. Since the other parame-
ters remain unchanged all dynamic properties of the model are
preserved.
We have used the mathematical approximation outlined above
to show that the MCN explains the observed in vivo pulsatile GCR
response to hypoglycemia triggered by switch-off signals in insulin
deﬁcient rats (Farhy et al., 2008; Farhy andMcCall, 2010) andother
key experimental ﬁndings. These results exemplify the excellent
agreement of the model predictions with the experimental obser-
vations.We note however, that this minimal model cannot explain
reports in which hyperglycemia paradoxically increases glucagon
levels (Olsen et al., 2005; Salehi et al., 2006).
In this work, the model of GCR is used to simulate the sys-
tem response to hypoglycemia and changes in BasG (AFI: model
parameter rGL,basal). To integrate Eq. 1 we used a Runge–Kutta
4 algorithm and its speciﬁc implementation within the software
package Berkeley-Madonna.
RESULTS
MEASURES OF GCR AND THEIR RELATIONSHIP WITH GLBASAL
The measured patient’s GLbasal,MaxG,CumG, and RIG are shown
in Table 1.
The calculated correlations between GLbasal and MaxG,CumG,
and RIG which quantify the relationships between GLbasal and
GCR are summarized in Table 2.
FIGURE 2 | Minimal control network (MCN) of glucagon secretion in
T1DM. AFR, auto-feedback regulated; AFI, auto-feedback independent.
Table 1 | Measures of basal glucagon and GCR in the study.
n=29 clamps Mean SD
GLbasal (pg/mL) 40.5 21.9
MaxG (pg/mL) 70.6 24.2
CumG (pg/mL×90min) 622.5 1675.9
RIG (%) 118.0 112.7
The correlations in Table 2 demonstrate that higher BasG levels
are associated with lower GCR response to hypoglycemia. In par-
ticular, there is a signiﬁcant negative relationship between GLbasal
and the measures of GCR which estimate the glucagon response
over its basal values, CumG and RIG.
Figure 3 shows the scattered plot of CumG vs. GLbasal showing
the negative relationship between these two markers.
As expected, themeasured estimate of the absoluteGCR,MaxG,
was positively correlated with GLbasal. However, the increase of
MaxG was slower than that of GLbasal as shown in Figure 4.
Since the correlation between RIG andGLbasal could depend on
the range of the data we use a bootstrap method which repeatedly
randomly permutes MaxG (10,000 times) to verify its signiﬁ-
cance. We found that the originally obtained very high correlation
(−0.738) have a p-value of 0.12 and is therefore not signiﬁcant.
Figure 5 illustrates the glucagon dynamics during hypo-
glycemia in two representative subjects with different GLbasal
Table 2 | Correlations between GLbasal and MaxG, CumG, and RIG.
CumG90 RIG MaxG
GLbasal Correlation −0.462 −0.738 0.584
p-Value 0.0116 <0.0001 <0.001
FIGURE 3 | Relationship between GLbasal and CumG90.
FIGURE 4 | Relationship between GLbasal and MaxG.
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values. The subject with a higher GLbasal had lower CumG, MaxG,
and RIG.
MODEL-BASED ANALYSIS
Figure 6 below shows the model response to hypoglycemia in two
different simulations performed with different values of the para-
meter rGL,basal, which resulted in different BasG levels (18 pg/mL
in the simulation depicted in the left panel and 28 pg/mL in the
simulation shown on the right – more than 50% increase).
To explore this further we performed a series of simulations in
which we varied the parameter rGL,basal in a way that the BasG lev-
els (before the decent into hypoglycemia) generally span the range
detected in the experiments (40.5± 20.9 pg/mL; Table 1). Table 3
shows the results of the simulations in terms of the same measures
that were used to assess the link between GLbasal and GCR in the
experimental data.
The left panel in Figure 7 depicts the relationship between
GLbasal and MaxG in which GLbasal varies between 25 and
65 pg/dL. This range was chosen to show that it is possible to
FIGURE 5 | Illustrative glucagon levels in two study participants.
ﬁnd a range that contains most of the experimentally observed
BasG values (in this case,>70%) in which the linear ﬁt has a slope
similar to the one shown in Figure 4. We note that the simu-
lated relationship between GLbasal and MaxG is clearly not linear
and when GLbasal increases it approximates the diagonal. In other
words, increase in GLbasal gradually obliterates the capacity of the
system to counterregulate above this basal value. In addition we
point out the fact that at the lower range of GLbasal the simulated
counterregulation response rapidly increases as GLbasal decreases
(see the ﬁrst couple of rows in Table 3).
The scattered plot on the right panel in Figure 7 shows the
link between the model predicted CumG and GLbasal. We note the
apparent negative relationship as observed in the experiments and
the rapid increase in CumG with further decrease in GLbasal.
DISCUSSION
In type 1 diabetes defective hormonal counterregulation is the
primary obstacle to achieving tight BG control. GCR disappears
during the course of the disease, but the mechanism behind the
GCR impairment remains unclear. In order to understand this
mechanism, we have developed a system-level approach com-
bining in vivo and in silico studies to reconstruct the primary
network interactions that control the glucagon release and GCR.
In the course of our recent studies we have developed a math-
ematical model of GCR which approximates the normal GCR
control axis and its impairment in diabetic rats (Farhy et al.,
2008; Farhy andMcCall, 2009a,b, 2010, 2011). Using thismodel we
have proposed two key network abnormalities which might con-
tribute to the defects in GCR: (i) absence of a switch-off trigger
or in other words, lack of constant intrapancreatic repression of
the α-cells which is released (switched-off) during hypoglycemia,
FIGURE 6 | Simulated glucagon response (black) to superimposed hypoglycemia (glucose levels shown in red) in two “in silico” subjects with low
(left) and high (right) basal glucagon.
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and (ii) elevated intraislet basal (AFI) glucagon secretion. Our
model-based work predicts and our animal work (Farhy et al.,
2008) supports the concept that both network abnormalities can
be attacked to repair, or at least partially reverse, the GCR defects.
Based on these predictions we have proposed clinical strategies
which use α-cell inhibitors to repair the defective GCR and sta-
bilize insulin deﬁcient diabetes (Farhy and McCall, 2011). So far
however, human studies addressing these predictions are scarce.
There exist some clinical data supporting the concept behind the
switch-off hypothesis (Banarer et al., 2002), but no data directly
addresses this issue (ii). Therefore, the goal of this work is to start
investigating the relevance of our predictions from animal data
and modeling to human pathophysiology in T1DM.
The results in this work support the validity of the concept
related to the second network abnormality (the GCR effects of
basal hyperglucagonemia) and conﬁrm the predictive power of
our existing GCR model in the context of human physiology. Our
data reﬂect the glucagon response to hypoglycemia in T1DM sub-
jects under tightly controlled glucose clamp conditions (Figure 1).
Several metrics were used to measure the GCR and their choice
Table 3 | MaxG, CumG, and RIG at different levels of GLbasal, which
span the range detected in the experiments.
GLbasal CumG90 RIG MaxG
15 6180 13.20 213
20 3750 6.25 145
25 1908 0.67 41.7
30 1572 0.46 43.8
35 1226.4 0.31 45.7
40 912 0.20 48
45 676.8 0.14 51.2
50 480.6 0.09 54.35
55 340.8 0.07 58.8
60 236.4 0.04 62.22
65 174 0.02 66.51
was directed by the understanding that efﬁcient defense against
dangerous low blood sugar drops requires increase of glucagon
levels during hypoglycemic episodes above the glucagon basal level
(concentration during euglycemia). Therefore, we used measures
that estimate GCR relative to the basal concentration (GLbasal):
CumG and RIG. We have found that higher BasG levels are asso-
ciated with reduction of the ability of the system to respond
adequately to hypoglycemiawith glucagon secretion thatmarkedly
exceeds the basal levels (Table 2; Figure 3). In absolute terms, the
maximal glucagon response to hypoglycemia (MaxG) is positively
linked to the basal level, but MaxG increases slower than GLbasal
(Figure 4) which supports the concept that in T1DM the GCR
generally cannot signiﬁcantly exceed the basal levels. Both ﬁnd-
ings appear consistent and were reproduced by our model. They
are in accordance with the proposed second network abnormal-
ity and support the recently formulated hypothesis that elevation
of BasG is part of the mechanism of GCR impairment in T1DM
(Farhy and McCall, 2011). We note that the very high negative
correlation between RIG and GLbasal may be partially a reﬂection
of a limited range of the data as detected by a bootstrap procedure
according to which this correlation was not signiﬁcant. However,
we would like to emphasize that even though this lack of detected
signiﬁcance does not support the concept that GLbasal and RIG are
linked, it suggests that a decrease of BasG levels as proposed else-
where (Farhy and McCall, 2011), may improve the effectiveness of
the GCR even in the face of a limited GCR response.
Model-based analysis was used to explain and replicate the
experimental observations. The simulations demonstrate that a
model of glucagon secretion in which one part of the α-cells
are feedback regulated and another is feedback independent
(Figure 2) can successfully replicate many aspects of the in vivo
behavior of the system (compare Figures 5 and 6). Except for
rescaling of the model output which leaves intact its dynamic
properties, no attempts were made to change the original para-
meters even though they have been determined to approximate
the rat GCR axis. This was done in order to test the extent to
which the rodent model can explain the human data without
changing its basic features or adding new model components. The
FIGURE 7 | Left: relationship between GLbasal and MaxG (the equation is the linear data fit) Right: relationship between GLbasal and CumG90.
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simulations showed that the model is consistent with the detected
negative correlation between CumG and GLbasal (Figure 7, left)
and with the observed slower growth of MaxG with respect to
GLbasal (Figure 7, right). From a network control point of view
this property of the system is due to a repression exerted by the
high AFI (basal) glucagon secretion on the auto-feedback depen-
dent (pulsatile) GCR as explained in our prior studies (Farhy and
McCall, 2009b, 2010). Thereby, our model is consistent with the
data and provides a putative mechanism for the experimentally
observed link between defective GCR and basal hyperglucagone-
mia. Additional simulations predict that with lowering the levels
of GLbasal (below the typical glucagon levels in T1DM) the sim-
ulated counterregulation response rapidly increases (see Table 3;
Figure 7, right), which is consistent with the previously proposed
strategy to repair the defective GCR by decreasing the glucagon
basal levels (Farhy and McCall, 2011) with α-cell inhibitors.
One limitation of our model is that some of the speciﬁcs in the
experimental data cannot be explained in the framework of the
current construct. In particular, our model cannot account for the
fact that in some study participants the glucagon response to hypo-
glycemia paradoxically went down with respect to their basal levels
(which accounts for some of the negative CumG values). Possible
explanations for this phenomenon could be anunaccounted exces-
sive variability or pulsatility of glucagon during euglycemia or the
already mentioned putative paradoxical stimulation of glucagon
by glucose (Olsen et al., 2005; Salehi et al., 2006). However, none
of these properties are currently part of the model, which may
require further extension and reﬁnement.
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